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Purpose. The aim of the present study was to investigate the atherosclerotic vascular damage in a consecutive series of patients
with AI and to correlate it with MSC. Methods. We studied 32 patients with AI matched with control subjects for age, sex, and
cardiovascular risk factors. Either patients or control subjects underwent MSC measurement as outpatients and carotid arteries
ultrasound (US) imaging studies. Results. The patients with AI had higher mean carotid artery IMT values and higher MSC levels
than control subjects. In a multivariate analysis performed in AI age was the best predictor for IMT.We have stratified patients and
control subjects by age (<60 yrs and ≥60 yrs). The patients showed significantly higher MSC levels than controls in both groups,
whereas significantly higher IMT values were observed only in older subjects.Conclusions. Patients withAI have signs of accelerated
atherosclerosis. Patients older than 60 years seemmore susceptible to the possible detrimental effect of subclinical hypercortisolism
on cardiovascular system. The MSC levels are not a strong predictor of the accelerated atherosclerosis, but they seem to indicate
the subtle but not autonomous cortisol excess that may potentially raise the cardiovascular risk.
1. Introduction
Clinically inapparent adrenal masses are discovered seren-
dipitously during diagnostic testing or treatment for unre-
lated disorders and are commonly known as adrenal inci-
dentaloma (AI) [1–3]. Improvement in imaging techniques
has resulted in the detection of an increasing number of AI,
whose numbers count millions of people worldwide [3]. In
5–47% of cases depending on different diagnostic protocols,
AI are associated with autonomous cortisol secretion that
is no longer under control of pituitary feedback [4–8].
This particular endocrine disorder, which has been called
subclinical Cushing’s syndrome (SCS) [9] or subclinical
autonomous glucocorticoid hypersecretion [2], is difficult to
characterize because of a spectrum of variation from normal-
ity to autonomy of cortisol secretion and since the degree of
cortisol excess is often minimal [2, 8, 10]. Notwithstanding
the uncertainty regarding definition of SCS, many patients
with the condition may be exposed to a chronic, low-grade
cortisol excess. Results from different studies support the
concept that this condition may confer an increased risk for
metabolic disorders and cardiovascular events [11–16].
Previous reports suggested that patients with Cushing’s
syndrome had severe atherosclerotic damage, as indicated
by reduced caliber, increased stiffness of carotid artery wall,
and increased prevalence of atherosclerotic plaques [11, 12].
However, there are conflicting data on the possibility that also
the low-grade cortisol excess characterizing SCS may cause
vascular damage [13, 14].
The aim of the present study was to investigate the
atherosclerotic vascular damage in a consecutive series of
patients with AI and to correlate it with midnight salivary
cortisol, as an outpatient measure of cortisol excess.
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2. Patients and Methods
2.1. Patients. We studied a consecutive, prospective series
of 32 patients with incidentally detected adrenocortical
adenoma [13 men, 19 women; median age 61.5 years, range:
37–74] referred to our center from January 1, 2013, to February
28, 2014. In all cases, AI were detected by an abdominal
CT scan done for unrelated diseases. The diagnosis of
cortical adenoma rested on the following CT criteria: size
less than 6.0 cm, regular shape with well-defined margins,
homogenous texture, and hypodense content. An attenuation
value of 10, or less, Hounsfield units on unenhanced CT
scan was considered suggestive of an adrenal adenoma.
The diagnosis of adenoma was confirmed by a repeat CT
scan after 3–6 months showing no significant increase in
mass size, or change in mass density, in any patient. The
patients with confirmed diagnosis of hyperaldosteronism or
pheochromocytoma were excluded.
We performed a 1 : 1 case-control analysis with 32 control
subjects matched for age, sex, BMI, smoking status, blood
pressure, glucose and lipid profile, and occurrence of previous
cardiovascular events. They were collected from the medical
staff and their relatives. All of the control subjects had
previous imaging exclusion of adrenal masses.
Either patients or control subjects were studied as outpa-
tients and they underwent careful clinical and history exami-
nation; none of them displayed specific signs or symptoms of
hypercortisolism, such as weakness associated with proximal
muscle wasting, skin atrophy, ecchymoses, or purple striae.
Moreover, none of them was receiving any drug known to
affect the hypothalamic-pituitary-adrenal axis or had current
or previous history of alcohol abuse ormajormood disorders.
Either patients or controls had an apparently normal sleep-
wake cycle.
Any subject with BMI greater than 30 kg/m2 was cat-
egorized as obese [17]. Any subject with systolic blood
pressure greater than 140mm Hg or diastolic blood pressure
greater than 90mm Hg or on antihypertensive treatment
was categorized as hypertensive [18]. Visit blood pressure
was the average of two seated measurements taken after
five minutes of rest by a physician using standardized
techniques. Diabetes mellitus was diagnosed if a subject
was on insulin or hypoglycemic agents or when the sub-
ject’s plasma glucose was greater than 7.0mmol/L at fasting
in at least two samples collected on different days [19].
Impaired fasting glucose was diagnosed when the subject’s
plasma glucose was between 6.1 and 7.0mmol/L at fasting
in at least two samples collected on different days [19].
Cardiovascular and cerebrovascular events were ascertained
by reviewing the patient discharge summaries and source
documents; complementary documentation was requested if
necessary. Cardiovascular events were validated according
to the principles used in randomized trials. The following
definitions were used: (a) myocardial infarction was defined
if there was hospitalization in the presence of 2 or more
of the symptoms, typical chest pain, electrocardiographic
changes, and increased cardiac enzyme concentrations, or by
the presence of typical ECG changes without any previous
acute symptoms (silent myocardial infarction); (b) angina
pectoris was diagnosed if there were hospitalization and chest
pain and documented electrocardiographic signs of coronary
ischemia or if there was a need for coronary revascularization
in the absence of acute myocardial infarction; (c) stroke
was diagnosed if there was hospitalization for a neurologic
deficit with symptoms continuing formore than 24 hours; (d)
transient ischemic attack (TIA) was defined as a neurologic
deficit lasting less than 24 hours. Smoking status was defined
as active if patients were current or former smokers.
The institutional review board approved the study, and all
subjects provided written, informed consent.
2.2. Methods. The patients with incidentally discovered
adrenal adenoma underwent a specific endocrine evaluation
as outpatients. It included (a) measurement of the 24-hour
excretion of urinary free cortisol (UFC), (b) measurement
of plasma ACTH at 8:00 a.m., and (c) overnight low-dose
dexamethasone suppression test (1mg, orally, at 11:00 p.m.
withmeasurement of serumcortisol at 8:00 a.m. the following
morning).
Either patients or control subjects underwent midnight
salivary cortisol (MSC) measurement as outpatients. They
were instructed to collect saliva samples at midnight. These
were obtained twice and were kept in a refrigerator for up to
1 week before being transferred to our reference laboratory.
Saliva was collected using Salivettes (Sarstedt, Newton, NC),
a cotton device that is placed in the mouth for 2min.
Before saliva collection, patients were instructed to rinse their
mouth without brushing their teeth (to avoid risk of gingival
bleeding). Midnight samples were collected after 4-5 h of
fasting (last food intake at 1900 or 2000 h). Amean of the two
collected samples was calculated. The MSC was determined
in our reference laboratory using commercially available kits
(RIA, Radim S.p.A., Rome, Italy). The assay sensitivity was
0.5 nmol/L. The intra- and interassay variations were 3 and
9%, respectively. Coefficients of variation in the high and
in the low range were, respectively, of 7 and 4%. Levels of
salivary cortisol below 8.3 nmol/L were considered in the
normal range. Concentrations were defined in a large series
of healthy subjects.
Serum and urinary cortisol were measured using com-
mercially available RIAs (Sorin Biomedica, Saluggia, Italy;
Radim S.p.A., Pomezia, Rome, Italy; Diagnostic Product Cor-
poration, Los Angeles, CA, USA). Intra-assay and interassay
coefficients of variation were 6% and 11.5%, respectively.
Plasma ACTH was measured by commercially available
immunoradiometric assays (CIS Biointernational, Gif-sur-
Yvette, France). Intra-assay coefficients of variation ranged
from 2.1 to 5.3% and interassay coefficients of variation
ranged from 3.1 to 8.9%, respectively; sensitivity ranged from
0.44 to 1.1 pmol/L.
SCS was considered in agreement with the recommen-
dations of the AME Position Statement [20]: no specific
clinical sign of cortisol excess and serumcortisol>138 nmol/L
after 1mg dexamethasone suppression test or serum cortisol
between 50 nmol/L and 138 nmol/L with one additional
alteration: UFC >414 nmol/24 h or ACTH <2.2 pmol/L.
Carotid arteries ultrasound imaging was performed in all
subjects by echo-Doppler ultrasonography (US), carried out
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with a Vingmed Sound CMF 725 (Horten, Norway) using
a 7.5MHz annular phased array transducer. Right and left
carotid arteries were scanned longitudinally, 2.5 cm proximal
to the bifurcation. The pictures were stored on magnetic
media and analyzed later. US imaging studieswere performed
by the same operator (B.A.), who was blinded to laboratory
assessment. Eachmeasurement was repeated three times, and
the mean was determined. Wall thickness of both carotid
arteries was investigated by measuring the intima media
thickness. In all subjects, the presence, location, and size of
plaques were also evaluated at the levels of common, internal,
and external carotid arteries.
2.3. Statistical Analysis. Rates and proportions were calcu-
lated for categorical data and means and standard deviations
for continuous data. Normality of data was assessed by the
Kolmogorov-Smirnov test. For continuous variables, differ-
ences were analyzed by means of the two-tailed Student’s 𝑡-
test when data were normally distributed and by using the
Mann-Whitney𝑈 test for nonparametric data. For categorical
variables, differences were analysed by means of the 𝜒2 test
with Yates correction. Levels of statistical significance were
set at 𝑝 < 0.05. All analyses were performed using the SPSS
software package version 21 (IBM).
3. Results
The characteristics of the patients with AI are reported in
Table 1. Eleven patients (34.4%) qualified for SCS and eight
patients (25%) had MSC >8.3 nmol/L, whereas in none of
the controls elevated MSC levels were observed. Eighteen
patients (56.2%) had hypertension and 16 patients (50%) had
hyperglycemia (Table 1).
The whole group of patients with AI had higher IMT
values than control subjects (left IMT: 0.069 ± 0.017 cm
versus 0.060 ± 0.010 cm, 𝑝 = 0.013; right IMT: 0.072 ±
0.018 cm versus 0.061 ± 0.010 cm, 𝑝 = 0.005). Four AI
patients had IMT values >0.9mm, while all of the controls
had IMT in the normal range. Well-defined carotid wall
plaques were detected in six patients (18.7%) and only in one
control subject (3.1%). Two patients had a plaque localized
at the level of the left carotid bifurcation with maximum
diameters of six mm and seven mm, respectively, whereas
four patients had a plaque at the level of the right internal
carotid artery with a maximal diameter ranging from six mm
to eightmm.Awell-defined carotidwall plaquewithmaximal
diameter of nine mm was detected in one control at level
of the right carotid artery bifurcation. The same figure was
observed whenwe considered the two groups of patients with
SCS or nonsecreting AI compared to the matched controls
(Table 2(a)), while the patients with SCS did not present
any significant difference for either IMT values or clinical
parameters in comparisonwith patients with nonsecretingAI
(Table 2(b)).
ThepatientswithAI hadhighermidnight salivary cortisol
levels than control subjects (5.90 ± 4.17 nmol/L versus 1.90 ±
0.77 nmol/L, 𝑝 < 0.0001). When patients were classified for
MSC levels (>8.3 nmol/L, Group A, and ≤8.3 nmol/L, Group
B) we have not observed any significant difference for either
IMT values or clinical parameters (Table 3(a)). However, both
groups had higher IMT values than the matched controls
(Table 3(b)).
In univariate analysis we have found a correlation at
the limit of the statistical significance between IMT and
hypertension (𝑟 = 0.378, 𝑝 = 0.062), smoking status (𝑝 =
0.372, 𝑝 = 0.067), or cortisol levels after 1mgDST (𝑟 = 0.363,
𝑝 = 0.074). A significant correlation has been found with
age (𝑟 = 0.478, 𝑝 = 0.016), while we have not found any
correlation between IMT and obesity, hyperglycemia, MSC,
UFC, or ACTH.
In a multivariate analysis performed in patients with AI
that included hypertension, smoking status, age, and cortisol
levels after 1mg DST, age was the best predictor for both left
IMT and right IMT (𝑟2 = 0.466, 𝑝 = 0.001). Therefore, we
have stratified patients and control subjects by age defining
2 groups (<60 years and ≥60 years) which represent the
mean age of the series. The patients showed significantly
higher MSC levels than controls in both age groups, whereas
significantly higher IMT values were observed only in older
subjects (Table 4).
4. Discussion
The present data demonstrate that patients with AI and of
60 years or more have higher carotid artery IMT values than
control subjects matched for age, sex, BMI, smoking status,
blood pressure, glycemic state, lipid profile, and occurrence of
previous cardiovascular events. Moreover, the overall group
of patients shows higher MSC levels in comparison with
control subjects. However, MSC was not a predictor of
increased IMT.
The link between cortisol and atherosclerosis is suggested
by fragments of information indicating that prolonged corti-
costeroid therapy accelerates the development of atheroscle-
rosis. In animal experiments, ACTH and cortisone were
shown to produce vascular injury and to enhance exper-
imentally induced atherosclerosis [21, 22]. In humans, the
use of glucocorticoids caused significant changes in vascular
connective tissue [23–25]. In addition, a cause and effect
relationship between corticosteroid treatment and premature
atherosclerosis was hypothesized in patients with rheumatoid
arthritis or systemic lupus erythematosus chronically treated
with glucocorticoids [26, 27]. Furthermore, a significant
association was found between coronary artery disease
and serum cortisol concentrations in patients subjected to
coronary angiography [24]. In patients with endogenous
hypercortisolism, the presence of atherosclerotic plaques or
preatherosclerotic lesions at the level of coronary or carotid
arteries has been previously demonstrated [11, 12, 28].
Several data from cross-sectional studies point to an
association between clinically inapparent cortisol excess and
some manifestations of the metabolic syndrome (arterial
hypertension, hyperglycemia, and overweight) and predispo-
sition to thrombosis and cardiovascular disease in patients
with adrenal incidentaloma [4, 13–15, 29–31].
Carotid IMT is generally recognized as a marker of early
atherosclerosis. In fact, ultrasound examination of the carotid
arteries with measurement of the IMT and detection of
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Table 2: Comparison of IMT values between SCS and nonsecreting
AIwith thematched controls (a). Comparison of clinical parameters
between patients with SCS and nonsecreting AI (b).
(a)
𝑁 Mean SD 𝑝 value
Left IMT (cm)
SCS 11 0.068 0.018 0.01
Controls 11 0.060 0.007
Right IMT (cm)
SCS 11 0.071 0.019 0.04
Controls 11 0.063 0.009
Left IMT (cm)
Nonsecreting 21 0.069 0.017 0.03
Controls 21 0.059 0.011
Right IMT (cm)
Nonsecreting 21 0.071 0.018 0.01
Controls 21 0.059 0.011
(b)
𝑁 Mean SD % 𝑝 value
Left IMT (cm)
SCS 11 0.068 0.018 NS
Nonsecreting 21 0.069 0.017
Right IMT (cm)
SCS 11 0.071 0.019 NS
Nonsecreting 21 0.071 0.018
Age (yrs)
SCS 11 60.2 9.3 NS
Nonsecreting 21 59.4 9.7
BMI (kg/m2)
SCS 11 27.7 5.1 NS
Nonsecreting 21 26.4 4.6
Mass size (cm)
SCS 11 2.8 0.7 NS
Nonsecreting 21 2.7 0.9
Hypertension (%)
SCS 11 63.6 NS
Nonsecreting 21 52.4
IGT/diabetes (%)
SCS 11 45.4 NS
Nonsecreting 21 47.6
SCS = subclinical Cushing syndrome, AI = adrenal incidentaloma, IMT =
intima media thickness, BMI = body mass index, IGT = impaired glucose
tolerance, 𝑁 = numbers of patients, SD = standard deviations, and NS =
not significant.
plaques has repeatedly been shown to predict occurrence of
both stroke and myocardial infarction. The relation between
carotid artery IMT and cardiovascular events is continuous,
but a threshold ≥0.9mm can be considered as a conservative
estimate of significant alteration [32].
In 2002 Tauchmanova` et al. [14] reported that carotid
IMT was significantly increased in patients with subclinical
cortisol excess compared with that in controls, suggesting
Table 3: Comparison of clinical parameters between patients with
MSC > 8.3 nmol/L (Group A) and ≤8.3 nmol/L (Group B) (a).
Comparison of IMT values between Group A and Group B with the
matched controls (b).
(a)
𝑁 Mean SD % 𝑝 value
Left IMT (cm)
Group A 8 0.068 0.024 NS
Group B 24 0.070 0.014
Right IMT (cm)
Group A 8 0.069 0.024 NS
Group B 24 0.071 0.016
Age (yrs)
Group A 8 58.2 12.4 NS
Group B 24 60.2 8.5
BMI (kg/m2)
Group A 8 28.3 5.6 NS
Group B 24 26.4 4.4
Mass size (cm)
Group A 8 2.5 0.4 NS
Group B 24 2.8 0.9
Hypertension (%)
Group A 8 62.5 NS
Group B 24 54.2
IGT/diabetes (%)
Group A 8 75.0 NS
Group B 24 71.4
(b)
𝑁 Mean SD 𝑝 value
Left IMT (cm)
Group A 8 0.066 0.024 0.01
Controls 8 0.0588 0.009
Right IMT (cm)
Group A 8 0.067 0.024 0.03
Controls 8 0.057 0.011
Left IMT (cm)
Group B 24 0.070 0.014 0.01
Controls 24 0.060 0.010
Right IMT (cm)
Group B 24 0.073 0.016 0.006
Controls 24 0.062 0.010
IMT = intima media thickness, BMI = body mass index, IGT = impaired
glucose tolerance,𝑁= numbers of patients, SD = standard deviations, and
NS = not significant.
a higher prevalence of systemic atherosclerosis, a concept
supported by the increased frequency of atherosclerotic
plaques. However, carotid IMT was not correlated with any
hormonal parameters. More recent studies have confirmed,
in different settings, increased IMT in patients with AI, either
with or without subclinical cortisol excess [29, 33, 34]. In
these papers, a more robust link between IMT and cortisol
6 International Journal of Endocrinology
Table 4: Comparison between patients and controls stratified by age.
Left IMT (cm) Right IMT (cm) Midnight salivary cortisol (nmol/L)
Patients (#16) Controls (#16) 𝑝 Patients (#16) Controls (#16) 𝑝 Patients (#16) Controls (#16) 𝑝
Age ≥ 60 yrs 0.075 ± 0.017 0.060 ± 0.012 0.005 0.077 ± 0.019 0.060 ± 0.012 0.006 5.85 ± 3.39 2.12 ± 0.66 0.001
Age < 60 yrs 0.061 ± 0.014 0.060 ± 0.008 NS 0.065 ± 0.015 0.060 ± 0.009 NS 5.98 ± 4.99 1.68 ± 0.77 0.002
levels has been demonstrated, in particular with morning
serum cortisol [29, 33, 34].
MSC is already an established test to screen patients
with suspected overt Cushing’s syndrome [35]. Nonetheless,
in patients with AI evaluation of MSC was powerless to
distinguish between nonsecreting adenoma and subclinical
cortisol excess [36, 37]. Thus, none of the studies have
evaluated MSC as a possible marker of increased IMT. MSC
has the obvious advantage of being more practical; thus it is
tempting to see if it can predict cardiovascular risk profile.
Only one paper showed a correlation between IMT and
morning salivary cortisol in healthy subjects [38]. In patients
with AI, we have previously demonstrated that elevated
midnight serum cortisol was associated with the elderly,
greater fasting glucose, and systolic blood pressure [16].
Our findings on IMT are in agreement with previous
studies confirming increased IMT and more wall plaque
in AI (secreting and nonsecreting) compared to controls.
Moreover, we have demonstrated that the whole group of
AI patients presents higher MSC levels than controls, and
25% of them had MSC levels higher than the upper limit
of normality. However, we have not confirmed a correlation
between IMT and hormonal and metabolic factors, whereas
the only predictor was age. We acknowledge the limit of a
reduced number of patients that may have hampered the
demonstration of a correlation between IMT and hormonal
variables. Moreover, the hormonal evaluations of patients
with AI remain controversial, since we use parameters that
are not representative of the possible persistent exposure
to cortisol excess. Thus, also patients with AI and formally
normal hormonal value should have metabolic alterations
and an increased cardiovascular risk. On the other hand the
strength has been to have designed our study to evaluate IMT
in patients with AI carefully matched to control subjects for
age and known cardiovascular risk factors. Nonetheless, our
data support the hypothesis that patients with AImay present
a worsened cardiovascular risk profile when compared to
the general population, as a possible consequence of being
exposed to a chronic cortisol excess, albeit of minimal
intensity. Patients with AI showed higher MSC than controls,
as an additional marker of an altered HPA axis. Additionally,
our data point out the importance of assessing IMT in
patients older than 60 years.
In conclusion, the present findings confirm that patients
with AI show signs of accelerated atherosclerosis compared
to matched controls. Patients older than 60 years seem more
compromised. Levels of MSC are not a strong predictor
of accelerated atherosclerosis, although further studies are
needed to fully evaluate whether MSC may be exploited as
a marker of subclinical cortisol excess that may potentially
raise cardiovascular risk.
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